S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
Log in
NASDAQ:BMRA

Biomerica Stock Forecast, Price & News

$5.60
-0.04 (-0.71 %)
(As of 10/20/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.52
Now: $5.60▼
$5.74
50-Day Range
$5.64
MA: $7.00▼
$7.85
52-Week Range
$2.05
Now: $5.60▼
$23.39
Volume90,732 shs
Average Volume877,908 shs
Market Capitalization$65.82 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.83
Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point-of-care and in-hospital/clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.33 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BMRA
Previous Symbol
CUSIPN/A
CIK73290
Webwww.biomerica.com
Phone949-645-2111
Employees54

Debt

Debt-to-Equity RatioN/A
Current Ratio10.00
Quick Ratio8.07

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.69 million
Price / Sales9.84
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.43 per share
Price / Book3.92

Profitability

EPS (Most Recent Fiscal Year)($0.23)
Net Income$-2,340,000.00
Net Margins-52.42%
Return on Equity-47.06%
Return on Assets-32.13%

Miscellaneous

Outstanding Shares11,753,000
Market Cap$65.82 million
Next Earnings Date1/20/2021 (Estimated)
OptionableNot Optionable
$5.60
-0.04 (-0.71 %)
(As of 10/20/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biomerica (NASDAQ:BMRA) Frequently Asked Questions

How has Biomerica's stock been impacted by Coronavirus (COVID-19)?

Biomerica's stock was trading at $2.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BMRA shares have increased by 93.1% and is now trading at $5.60.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Biomerica?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Biomerica.

When is Biomerica's next earnings date?

Biomerica is scheduled to release its next quarterly earnings announcement on Wednesday, January 20th 2021.
View our earnings forecast for Biomerica.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) released its quarterly earnings data on Thursday, October, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.06. The firm earned $1.14 million during the quarter, compared to the consensus estimate of $1.09 million. Biomerica had a negative net margin of 52.42% and a negative return on equity of 47.06%.
View Biomerica's earnings history.

What price target have analysts set for BMRA?

2 brokerages have issued 12 month price targets for Biomerica's stock. Their forecasts range from $11.00 to $11.00. On average, they expect Biomerica's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 96.4% from the stock's current price.
View analysts' price targets for Biomerica.

Are investors shorting Biomerica?

Biomerica saw a decrease in short interest in the month of September. As of September 30th, there was short interest totaling 665,300 shares, a decrease of 17.5% from the September 15th total of 806,300 shares. Based on an average daily volume of 532,300 shares, the short-interest ratio is currently 1.2 days. Currently, 7.4% of the company's shares are short sold.
View Biomerica's Short Interest.

Who are some of Biomerica's key competitors?

Some companies that are related to Biomerica include Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), OncoCyte (OCX), OncoCyte (OCX), Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), Trinity Biotech (TRIB), ImmuCell (ICCC), GeneNews (GNWSF), StageZero Life Sciences (GNWSD), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), Akers Biosciences (AKER), BG Medicine (BGMD) and FluoroPharma Medical (FPMI).
View all competitors.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), Opko Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

Who are Biomerica's key executives?

Biomerica's management team includes the following people:
  • Mr. Zackary S. Irani, Chairman & CEO (Age 53)
  • Ms. Janet Moore, CFO, Treasurer, Sec. & Director (Age 68)

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $5.60.

How big of a company is Biomerica?

Biomerica has a market capitalization of $65.82 million and generates $6.69 million in revenue each year. The company earns $-2,340,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Biomerica employs 54 workers across the globe.

What is Biomerica's official website?

The official website for Biomerica is www.biomerica.com.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111.

This page was last updated on 10/20/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.